Difference between revisions of "CCND2-AS1"
Guangyu Wang (talk | contribs) (Created page with "==Annotated Information== ===Approved Symbol=== CCND2-AS1 ===Approved Name=== CCND2 antisense RNA 1 ===Previous Symbols=== _ ===Synonyms=== _ ===Chromosome=== 12p13.32 ===RefS...") |
|||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==Annotated Information== | ==Annotated Information== | ||
| − | === | + | ===Name=== |
| − | CCND2-AS1 | + | CCND2-AS1:CCND2 antisense RNA 1 |
| − | + | ===Function=== | |
| − | CCND2 antisense RNA 1 | + | [[File:CCND2-AS1.jpg|right|thumb|400px|'''''CCND2-AS1'' regulates Wnt/β-catenin signaling in glioma cell lines'''<ref name="ref1" />.]] |
| − | === | + | CCND2-AS1 promotes glioma cell proliferation through Wnt/β-catenin signaling and it might function as a potential novel therapeutic target for the treatment of glioma <ref name="ref1" />. Knockdown CCND2-AS1 can inhibit the proliferation and colony formation, induce the cell cycle arrest in G0/G1 phase <ref name="ref1" />. Overexpression CCND2-AS1 promotes cell growth in normal human astrocyte, and highly expressed CCND2-AS1 could enhance Wnt/b-catenin signaling in glioma <ref name="ref1" />. |
| − | + | ===Expression=== | |
| − | === | + | CCND2-AS1 is up-regulated in glioma tissues compared with adjacent normal brain tissues <ref name="ref1" />. |
| − | + | ===Disease=== | |
| − | === | + | Glioma <ref name="ref1" /> |
| − | + | ===Sequence=== | |
| − | === | + | >NR_125790.1 Homo sapiens CCND2 antisense RNA 1 (CCND2-AS1), transcript variant 3, long non-coding RNA |
| − | + | <dnaseq>AATGCACAGCTTCTCCGCGGTCAGCGGGCTGGTCTCTTTGAGTTTGGAGGCCAGGAACATGCAGACAGCA | |
| − | === | + | CCCAGGAGTTGCAGATGGGACTTCGGAGTCGGGACCCCAGCCAAGAAACGGTCCAGAAGAATCTACCATA |
| − | + | AAACCAACAGACTCCTCCTGATCTCTACCTGTGCTGTCTGCCTCTCTAGTTCCGGACACTGAGAGCTGGT | |
| − | == | + | GCCCTGTGGCCACCTCAAGCTGGAACCCTGCAAGATCACCAAGAAGACTGCATGCCTCGCTCTAGCCTTC |
| − | + | CTAAGGGAAAGTAGACTCCTGTTTTTGAGAGAAATTACCTGATTTCAAGAGAAACATAAAGGACTTTTTT | |
| − | == | + | TCCCTTAACATTCCACTCGTAAAAATGAAGTTTGGAAGAACTTCTGCAAACTCTGAGTGTTTTGGTCAAT |
| − | + | TGACCTTTTACTGTACTAAGCAAATCTGAAGCCACAAATACATTGGGGAGGAAGGTATACCCTTCACAAA | |
| + | AGATCCGTCACTTAGCCAGATACTCTGTTGCCATGCTTCTTTAAATAAAGCACATTTCTGGTA</dnaseq> | ||
| + | ==Labs working on this lncRNA== | ||
| + | * Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. | ||
| + | ==References== | ||
| + | <references> | ||
| + | <ref name="ref1"> | ||
| + | Zhang H, Wei DL, Wan L, Yan SF, Sun YH. Highly expressed lncRNA CCND2-AS1 | ||
| + | promotes glioma cell proliferation through Wnt/β-catenin signaling. Biochem | ||
| + | Biophys Res Commun. 2017 Jan 22;482(4):1219-1225. | ||
| + | </ref> | ||
| + | </references> | ||
Latest revision as of 05:44, 17 November 2017
Contents
Annotated Information
Name
CCND2-AS1:CCND2 antisense RNA 1
Function
CCND2-AS1 regulates Wnt/β-catenin signaling in glioma cell lines[1].
CCND2-AS1 promotes glioma cell proliferation through Wnt/β-catenin signaling and it might function as a potential novel therapeutic target for the treatment of glioma [1]. Knockdown CCND2-AS1 can inhibit the proliferation and colony formation, induce the cell cycle arrest in G0/G1 phase [1]. Overexpression CCND2-AS1 promotes cell growth in normal human astrocyte, and highly expressed CCND2-AS1 could enhance Wnt/b-catenin signaling in glioma [1].
Expression
CCND2-AS1 is up-regulated in glioma tissues compared with adjacent normal brain tissues [1].
Disease
Glioma [1]
Sequence
>NR_125790.1 Homo sapiens CCND2 antisense RNA 1 (CCND2-AS1), transcript variant 3, long non-coding RNA
000001 AATGCACAGC TTCTCCGCGG TCAGCGGGCT GGTCTCTTTG AGTTTGGAGG CCAGGAACAT GCAGACAGCA CCCAGGAGTT 000080
000081 GCAGATGGGA CTTCGGAGTC GGGACCCCAG CCAAGAAACG GTCCAGAAGA ATCTACCATA AAACCAACAG ACTCCTCCTG 000160
000161 ATCTCTACCT GTGCTGTCTG CCTCTCTAGT TCCGGACACT GAGAGCTGGT GCCCTGTGGC CACCTCAAGC TGGAACCCTG 000240
000241 CAAGATCACC AAGAAGACTG CATGCCTCGC TCTAGCCTTC CTAAGGGAAA GTAGACTCCT GTTTTTGAGA GAAATTACCT 000320
000321 GATTTCAAGA GAAACATAAA GGACTTTTTT TCCCTTAACA TTCCACTCGT AAAAATGAAG TTTGGAAGAA CTTCTGCAAA 000400
000401 CTCTGAGTGT TTTGGTCAAT TGACCTTTTA CTGTACTAAG CAAATCTGAA GCCACAAATA CATTGGGGAG GAAGGTATAC 000480
000481 CCTTCACAAA AGATCCGTCA CTTAGCCAGA TACTCTGTTG CCATGCTTCT TTAAATAAAG CACATTTCTG GTA
000081 GCAGATGGGA CTTCGGAGTC GGGACCCCAG CCAAGAAACG GTCCAGAAGA ATCTACCATA AAACCAACAG ACTCCTCCTG 000160
000161 ATCTCTACCT GTGCTGTCTG CCTCTCTAGT TCCGGACACT GAGAGCTGGT GCCCTGTGGC CACCTCAAGC TGGAACCCTG 000240
000241 CAAGATCACC AAGAAGACTG CATGCCTCGC TCTAGCCTTC CTAAGGGAAA GTAGACTCCT GTTTTTGAGA GAAATTACCT 000320
000321 GATTTCAAGA GAAACATAAA GGACTTTTTT TCCCTTAACA TTCCACTCGT AAAAATGAAG TTTGGAAGAA CTTCTGCAAA 000400
000401 CTCTGAGTGT TTTGGTCAAT TGACCTTTTA CTGTACTAAG CAAATCTGAA GCCACAAATA CATTGGGGAG GAAGGTATAC 000480
000481 CCTTCACAAA AGATCCGTCA CTTAGCCAGA TACTCTGTTG CCATGCTTCT TTAAATAAAG CACATTTCTG GTA
Labs working on this lncRNA
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
